Stephano Del Prato (Stefano Del Prato)

Scopus Author ID ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 62

Top Venues

Diabetes, obesity & metabolism

Diabetes care

Diabetologia

Diabetes/metabolism research and reviews

Università degli Studi di Pisa Facoltà di Medicina e Chirurgia

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Università degli Studi di Pisa Facoltà di Medicina e Chirurgia Nov 01 2002

Italy

Full Professor of Endocrinology

Università degli Studi di Pisa Facoltà di Medicina e Chirurgia Nov 01 2000 - Oct 31 2002

Italy

Associate Professor of Endocrinology

Università degli Studi di Padova Nov 02 1992 - Oct 31 2000

Italy

Associate Professor of Endocrinology

Ospedale Civile di Padova Nov 11 1987 - Oct 31 1992

Italy

Aiuto Corresponsabile

The University of Texas Health Science Center at San Antonio Official Bookstore Oct 01 1988 - Apr 30 1990

United States

Associate professor :: Medicine

Ospedale Civile di Padova Feb 04 1982 - Nov 10 1987

Italy

Assistente Medico

Publications

Ulagamadesan Venkatesan, Mu Yang, Shun Fu Lee, Kelley R H Branch, Stephano Del Prato, Carolyn Su Ping Lam, Renato D Lopes, Richard Pratley, Julio Rosenstock, Naveed Sattar
Do nonglycaemic effects such as weight loss account for HbA1c lowering with efpeglenatide?: Insights from the AMPLITUDE-O trial. Diabetes, obesity & metabolism (2024)
Carol Wysham, Harpreet S Bajaj, Stephano Del Prato, Denise Reis Franco, Arihiro Kiyosue, Dominik Dahl, Chunmei Zhou, Molly C Carr, Michael Case, Livia Firmino Gonçalves, null null
Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment. The New England journal of medicine (2024)
Ramzi A Ajjan, Tadej Battelino, Xavier Cos, Stephano Del Prato, Jean-Christophe Philips, Laurent Meyer, Jochen Seufert, Samuel Seidu
Continuous glucose monitoring for the routine care of type 2 diabetes mellitus. Nature reviews. Endocrinology (2024)
Thomas Forst, Christophe E M De Block, Stephano Del Prato, Sara Armani, Juan Pablo Frias, Anne Lautenbach, Bernhard Ludvik, Marina Marinez, Chantal Mathieu, Timo Dirk Müller, Oliver Schnell
The role of incretin receptor agonists in the treatment of obesity. Diabetes, obesity & metabolism (2024)
Stephano Del Prato, Bart Torbeyns, Chantal Mathieu, null null
2024: The year to take European action on diabetes to the next level. Diabetologia 67 (7) (2024)
Ramzi A Ajjan, Tadej Battelino, Xavier Cos, Stephano Del Prato, Jean-Christophe Philips, Laurent Meyer, Jochen Seufert, Samuel Seidu
Continuous glucose monitoring for the routine care of type 2 diabetes mellitus. Nature reviews. Endocrinology 20 (7) (2024)
Giuseppe Daniele, Andrea Tura, Alex Brocchi, Alessandro Saba, Beatrice Campi, Veronica Sancho-Bornez, Angela Dardano, Stephano Del Prato
β-Cell Function, Incretin Effect, and Glucose Kinetics in Response to a Mixed Meal in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin. Diabetes care (2024)
Gian Poalo Fadini, Enrico Longato, Mario Luca Morieri, Enzo Bonora, Agostino Consoli, Bruno Fattor, Mauro Rigato, Federica Turchi, Stephano Del Prato, Angelo Avogaro, Anna Solini, null null
Comparative renal outcomes of matched cohorts of patients with type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists under routine care. Diabetologia (2024)
Stephano Del Prato, Bart Torbeyns, Chantal Mathieu, null null
2024: The year to take European action on diabetes to the next level. Diabetologia 67 (7) (2024)
Giuseppe Daniele, Andrea Tura, Alex Brocchi, Alessandro Saba, Beatrice Campi, Veronica Sancho-Bornez, Angela Dardano, Stephano Del Prato
β-Cell Function, Incretin Effect, and Glucose Kinetics in Response to a Mixed Meal in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin. Diabetes care 47 (7) (2024)
Ramzi A Ajjan, Tadej Battelino, Xavier Cos, Stephano Del Prato, Jean-Christophe Philips, Laurent Meyer, Jochen Seufert, Samuel Seidu
Continuous glucose monitoring for the routine care of type 2 diabetes mellitus. Nature reviews. Endocrinology 20 (7) (2024)
Stephano Del Prato, Bart Torbeyns, Chantal Mathieu, null null
2024: The year to take European action on diabetes to the next level. Diabetologia (2024)
Mahmoud Ibrahim, Ebtesam M Ba-Essa, Jason Baker, Avivit Cahn, Antonio Ceriello, Francesco Cosentino, Melanie Jane Davies, Robert H Eckel, Luc Van Gaal, Peter Haulund Gaede, Yehuda Handelsman, Samuel Klein, Richard David Leslie, Paolo Pozzilli, Stephano Del Prato, Francesco Prattichizzo, Oliver Schnell, Petar M Seferović, Eberhard Standl, Abraham Thomas, Jaakko Tuomilehto, Paul Valensi, Guillermo E Umpierrez
Cardio-renal-metabolic disease in primary care setting. Diabetes/metabolism research and reviews (2023)
Ulagamadesan Venkatesan, Rajibul Mian, Chinthanie Ramasundarahettige, Kelley R H Branch, Stephano Del Prato, Carolyn Su Ping Lam, Renato D Lopes, Richard Pratley, Julio Rosenstock, Naveed Sattar
Cardiovascular and renal outcomes with varying degrees of kidney disease in high-risk people with type 2 diabetes: An epidemiological analysis of data from the AMPLITUDE-O trial. Diabetes, obesity & metabolism 26 (4) (2023)
Ulagamadesan Venkatesan, Zhuoru Li, Chinthanie Ramasundarahettige, SeungJae Baek, Kelley R H Branch, Stephano Del Prato, Carolyn Su Ping Lam, Renato Deláscio Lopes, Richard E Pratley, Julio Rosenstock, Naveed Sattar
Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial. Circulation (2023)
Julio Rosenstock, Luis Vázquez, Stephano Del Prato, Denise Reis Franco, Govinda Weerakkody, Biyue Dai, Laura Fernández Landó, Brandon K Bergman, Angel Rodríguez
Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1-4 Trials. Diabetes care (2023)
Mahmoud Ibrahim, Ebtesam M Ba-Essa, Jason Baker, Avivit Cahn, Antonio Ceriello, Francesco Cosentino, Melanie Jane Davies, Robert H Eckel, Luc Van Gaal, Peter Haulund Gaede, Yehuda Handelsman, Samuel Klein, Richard David Leslie, Paolo Pozzilli, Stephano Del Prato, Francesco Prattichizzo, Oliver Schnell, Petar M Seferović, Eberhard Standl, Abraham Thomas, Jaakko Tuomilehto, Paul Valensi, Guillermo E Umpierrez
Cardio-renal-metabolic disease in primary care setting. Diabetes/metabolism research and reviews 40 (3) (2023)
Mahmoud Ibrahim, Ebtesam M Ba-Essa, Jason Baker, Avivit Cahn, Antonio Ceriello, Francesco Cosentino, Melanie Jane Davies, Robert H Eckel, Luc Van Gaal, Peter Haulund Gaede, Yehuda Handelsman, Samuel Klein, Richard David Leslie, Paolo Pozzilli, Stephano Del Prato, Francesco Prattichizzo, Oliver Schnell, Petar M Seferović, Eberhard Standl, Abraham Thomas, Jaakko Tuomilehto, Paul Valensi, Guillermo E Umpierrez
Cardio-renal-metabolic disease in primary care setting. Diabetes/metabolism research and reviews 40 (3) (2023)
Mahmoud Ibrahim, Ebtesam M Ba-Essa, Jason Baker, Avivit Cahn, Antonio Ceriello, Francesco Cosentino, Melanie Jane Davies, Robert H Eckel, Luc Van Gaal, Peter Haulund Gaede, Yehuda Handelsman, Samuel Klein, Richard David Leslie, Paolo Pozzilli, Stephano Del Prato, Francesco Prattichizzo, Oliver Schnell, Petar M Seferović, Eberhard Standl, Abraham Thomas, Jaakko Tuomilehto, Paul Valensi, Guillermo E Umpierrez
Cardio-renal-metabolic disease in primary care setting. Diabetes/metabolism research and reviews 40 (3) (2023)
Mahmoud Ibrahim, Ebtesam M Ba-Essa, Jason Baker, Avivit Cahn, Antonio Ceriello, Francesco Cosentino, Melanie Jane Davies, Robert H Eckel, Luc Van Gaal, Peter Haulund Gaede, Yehuda Handelsman, Samuel Klein, Richard David Leslie, Paolo Pozzilli, Stephano Del Prato, Francesco Prattichizzo, Oliver Schnell, Petar M Seferović, Eberhard Standl, Abraham Thomas, Jaakko Tuomilehto, Paul Valensi, Guillermo E Umpierrez
Cardio-renal-metabolic disease in primary care setting. Diabetes/metabolism research and reviews 40 (3) (2023)
Ulagamadesan Venkatesan, Rajibul Mian, Chinthanie Ramasundarahettige, Kelley R H Branch, Stephano Del Prato, Carolyn Su Ping Lam, Renato D Lopes, Richard Pratley, Julio Rosenstock, Naveed Sattar
Cardiovascular and renal outcomes with varying degrees of kidney disease in high-risk people with type 2 diabetes: An epidemiological analysis of data from the AMPLITUDE-O trial. Diabetes, obesity & metabolism (2023)
Anna Solini, Domenico Tricò, Stephano Del Prato
Incretins and cardiovascular disease: to the heart of type 2 diabetes? Diabetologia (2023)
Mahmoud Ibrahim, Ebtesam M Ba-Essa, Jason Baker, Avivit Cahn, Antonio Ceriello, Francesco Cosentino, Melanie Jane Davies, Robert H Eckel, Luc Van Gaal, Peter Haulund Gaede, Yehuda Handelsman, Samuel Klein, Richard David Leslie, Paolo Pozzilli, Stephano Del Prato, Francesco Prattichizzo, Oliver Schnell, Petar M Seferović, Eberhard Standl, Abraham Thomas, Jaakko Tuomilehto, Paul Valensi, Guillermo E Umpierrez
Cardio-renal-metabolic disease in primary care setting. Diabetes/metabolism research and reviews 40 (3) (2023)
Ulagamadesan Venkatesan, Rajibul Mian, Chinthanie Ramasundarahettige, Kelley R H Branch, Stephano Del Prato, Carolyn Su Ping Lam, Renato D Lopes, Richard Pratley, Julio Rosenstock, Naveed Sattar
Cardiovascular and renal outcomes with varying degrees of kidney disease in high-risk people with type 2 diabetes: An epidemiological analysis of data from the AMPLITUDE-O trial. Diabetes, obesity & metabolism 26 (4) (2023)
Melanie Jane Davies, Vanita R Aroda, Billy S Collins, Robert A Gabbay, Jennifer Green, Nisa M Maruthur, Sylvia E Rosas, Stephano Del Prato, Chantal Mathieu, Geltrude Mingrone, Ellen Burgess, Tsvetalina Tankova, Apostolos Tsapas, John B Buse
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes care 45 (11) (2022)
Melanie Jane Davies, Vanita R Aroda, Billy S Collins, Robert A Gabbay, Jennifer Green, Nisa M Maruthur, Sylvia E Rosas, Stephano Del Prato, Chantal Mathieu, Geltrude Mingrone, Ellen Burgess, Tsvetalina Tankova, Apostolos Tsapas, John B Buse
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 65 (12) (2022)
Chantal Mathieu, Jeannette Soderberg, Stephano Del Prato, Anne-Marie Felton, Xavier Cos, Carine de Beaufort, Jean-François Gautier, Bastian Hauck, Angus Forbes, Robert Heine, Peter Schwarz, Bart Torbeyns, null null
The European Diabetes Forum (EUDF): a forum for turning the tide on diabetes in Europe. Diabetologia (2022)
Thomas Karagiannis, Ioannis Avgerinos, Aris Liakos, Stephano Del Prato, David R Matthews, Apostolos Tsapas, Apostolos Tsapas
Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia 65 (8) (2022)
Andrea Giaccari, Anna Solini, Simona Frontoni, Stephano Del Prato
Metformin Benefits: Another Example for Alternative Energy Substrate Mechanism? Diabetes care 44 (3) (2021)
Julio Rosenstock, Lawrence Blonde, Vanita R Aroda, Juan Pablo Frias, Elisabeth Souhami, Chen Ji, Elisabeth Niemoeller, Stephano Del Prato
Switching to iGlarLixi versus continuation of a daily or weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) in insufficiently controlled type 2 diabetes: A LixiLan-G trial subgroup analysis by HbA1c and GLP-1 RA use at screening. Diabetes, obesity & metabolism 23 (6) (2021)
Monia Garofolo, Elisa Gualdani, Cristina Bianchi, Michele Aragona, Fabrizio Campi, Daniela Lucchesi, Giuseppe Daniele, Roberto Miccoli, Paolo Francesconi, Stephano Del Prato, Giuseppe Penno
Response to Comment on Garofolo et al. Insulin Resistance and Risk of Major Vascular Events and All-Cause Mortality in Type 1 Diabetes: A 10-Year Follow-up Study. Diabetes Care 2020;43:e139-e141. Diabetes care 44 (4) (2021)
Silvana Galderisi, Marc De Hert, Stephano Del Prato, Andrea Fagiolini, Philip Gorwood, Stefan Leucht, Aldo Pietro Maggioni, Armida Mucci, Celso Arango
Identification and management of cardiometabolic risk in subjects with schizophrenia spectrum disorders: A Delphi expert consensus study. European psychiatry : the journal of the Association of European Psychiatrists 64 (1) (2021)
Carolyn Su Ping Lam, Chinthanie Ramasundarahettige, Kelley R H Branch, Naveed Sattar, Julio Rosenstock, Richard E Pratley, Stephano Del Prato, Renato Deláscio Lopes, Elisabeth Niemoeller, Nardev S Khurmi, SeungJae Baek, Hertzel C Gerstein
Efpeglenatide and Clinical Outcomes with and without Concomitant Sodium-Glucose Co-Transporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial. Circulation (2021)
Vasudha Ahuja, Pasi Aronen, T A Pramodkumar, Helen Looker, Angela Chetrit, Aini H Bloigu, Auni Juutilainen, Cristina Bianchi, Lucia La Sala, Ranjit Mohan Anjana, Rajendra Pradeepa, Ulagamadesan Venkatesan, Sarvanan Jebarani, Viswanathan Baskar, Teresa Vanessa Fiorentino, Patrick Timpel, Ralph A De Fronzo, Antonio Ceriello, Stephano Del Prato, Muhammad A Abdul-Ghani, Sirkka Keinänen-Kiukaanniemi, Rachel Dankner, Peter H Bennett, William C Knowler, Peter Schwarz, Giorgio Sesti, Rie Oka, Viswanathan Mohan, Leif Groop, Jaakko Tuomilehto, Samuli Ripatti, Michael Bergman, Tiinamaija Tuomi
Accuracy of 1-Hour Plasma Glucose During the Oral Glucose Tolerance Test in Diagnosis of Type 2 Diabetes in Adults: A Meta-analysis. Diabetes care 44 (4) (2021)
Giuseppe Daniele, Claudia Lunghi, Angela Dardano, Paola Binda, Giovanni Ceccarini, Ferruccio Santini, Laura Giusti, Annamaria Ciccarone, Rosario Bellini, Carlo Moretto, Maria Concetta Morrone, Stephano Del Prato
Bariatric surgery restores visual cortical plasticity in nondiabetic subjects with obesity. International journal of obesity (2005) 45 (8) (2021)
Lawrence Blonde, Julio Rosenstock, Juan Pablo Frias, Andreas L Birkenfeld, Elisabeth Niemoeller, Elisabeth Souhami, Chen Ji, Stephano Del Prato, Vanita R Aroda
Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study. Diabetes care 44 (3) (2021)
Gian Poalo Fadini, Stephano Del Prato, Angelo Avogaro, Anna Solini
Challenges and opportunities in real-world evidence on the renal effects of sodium-glucose cotransporter-2 inhibitors. Diabetes, obesity & metabolism (2021)
Carolina Solis-Herrera, Giuseppe Daniele, Mariam Alatrach, Christina Agyin, Curtis Triplitt, John Adams, Rupal Patel, Francesco Rubino, Henri Honka, Xi Chen, Muhammad Abdul-Ghani, Eugenio Cersosimo, Stephano Del Prato, Ralph A De Fronzo
Increase in Endogenous Glucose Production With SGLT2 Inhibition Is Unchanged by Renal Denervation and Correlates Strongly With the Increase in Urinary Glucose Excretion. Diabetes care 43 (5) (2020)
Stephano Del Prato
How conclusive is the CONCLUDE trial? Diabetologia 63 (4) (2020)
Jamie Hartmann-Boyce, Elizabeth Morris, Clare Goyder, Jade Kinton, James Perring, David Nunan, Kamal Mahtani, John B Buse, Stephano Del Prato, Linong Ji, Ronan Roussel, Kamlesh Khunti F MedSci
Diabetes and COVID-19: Risks, Management, and Learnings From Other National Disasters. Diabetes care 43 (8) (2020)
Giuseppe Daniele, Carolina Solis-Herrera, Angela Dardano, Andrea Mari, Andrea Tura, Laura Giusti, Jancy J Kurumthodathu, Beatrice Campi, Alessandro Saba, Anna Maria Bianchi, Carla Tregnaghi, Maria Francesca Egidi, Muhammad Abdul-Ghani, Ralph DeFronzo, Stephano Del Prato
Increase in endogenous glucose production with SGLT2 inhibition is attenuated in individuals who underwent kidney transplantation and bilateral native nephrectomy. Diabetologia 63 (11) (2020)
Juliana Chung Ngor Chan, Päivi M Paldánius, Chantal Mathieu, Michael Stumvoll, David R Matthews, Stephano Del Prato
Early combination therapy delayed treatment escalation in newly diagnosed young-onset type 2 diabetes: A subanalysis of the VERIFY study. Diabetes, obesity & metabolism 23 (1) (2020)
Stephano Del Prato, Juan Pablo Frias, Lawrence Blonde, Vanita R Aroda, Niam Shehadeh, Aramesh Saremi, Terry Dex, Elisabeth Niemoeller, Elisabeth Souhami, Minzhi Liu, Julio Rosenstock
Impact of disease duration and β-cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on glucagon-like peptide-1 receptor agonist therapy: Exploratory analyses from the LixiLan-G trial. Diabetes, obesity & metabolism 22 (9) (2020)
Stephano Del Prato, Jahoon Kang, Michael E Trautmann, John Stewart, Christopher H Sorli, Michael Derwahl, Alfonso Soto, Kun-Ho Yoon
Efficacy and safety of once-monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo-controlled, 16-week randomized dose-finding study. Diabetes, obesity & metabolism 22 (7) (2020)
Ulagamadesan Venkatesan, Kelley Branch, Laura Heenan, Stephano Del Prato, Nardev S Khurmi, Carolyn S P Lam, Richard Pratley, Julio Rosenstock, Naveed Sattar
Design and baseline characteristics of the AMPLITUDE-O cardiovascular outcomes trial of efpeglenatide, a weekly glucagon-like peptide-1 receptor agonist. Diabetes, obesity & metabolism 23 (2) (2020)
Alberto Coppelli, Rosa Giannarelli, Michele Aragona, Giuseppe Penno, Marco Falcone, Giusy Tiseo, Lorenzo Ghiadoni, Greta Barbieri, Fabio Monzani, Agostino Virdis, Francesco Menichetti, Stephano Del Prato, null null
Hyperglycemia at Hospital Admission Is Associated With Severity of the Prognosis in Patients Hospitalized for COVID-19: The Pisa COVID-19 Study. Diabetes care 43 (10) (2020)
Monia Garofolo, Elisa Gualdani, Maria Giovanna Scarale, Cristina Bianchi, Michele Aragona, Fabrizio Campi, Daniela Lucchesi, Giuseppe Daniele, Roberto Miccoli, Paolo Francesconi, Stephano Del Prato, Giuseppe Penno
Insulin Resistance and Risk of Major Vascular Events and All-Cause Mortality in Type 1 Diabetes: A 10-Year Follow-up Study. Diabetes care 43 (10) (2020)
Amit Akirov, Avivit Cahn, Stephano Del Prato, Philip D Home, Luc Van Gaal, Juliana Chan, Guang Ning, Itamar Raz
Tackling obesity during the COVID-19 pandemic. Diabetes/metabolism research and reviews 37 (3) (2020)
Monia Garofolo, Elisa Gualdani, Rosa Giannarelli, Michele Aragona, Fabrizio Campi, Daniela Lucchesi, Giuseppe Daniele, Roberto Miccoli, Paolo Francesconi, Stephano Del Prato, Giuseppe Penno
Microvascular complications burden (nephropathy, retinopathy and peripheral polyneuropathy) affects risk of major vascular events and all-cause mortality in type 1 diabetes: a 10-year follow-up study. Cardiovascular diabetology 18 (1) (2019)
Giuseppe Daniele, Andrea Tura, Angela Dardano, Alessandra Bertolotto, Cristina Bianchi, Laura Giusti, Jancy Joseph Kurumthodathu, Stephano Del Prato
Effects of treatment with metformin and/or sitagliptin on beta-cell function and insulin resistance in prediabetic women with previous gestational diabetes. Diabetes, obesity & metabolism 22 (4) (2019)
Angelo Avogaro, Gian Poalo Fadini, Stephano Del Prato
Reinterpreting Cardiorenal Protection of Renal Sodium-Glucose Cotransporter 2 Inhibitors via Cellular Life History Programming. Diabetes care 43 (3) (2019)
Clifford J Bailey, Stephano Del Prato, Cheryl Wei, Daniel Reyner, Gabriela Saraiva
Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes. Diabetes, obesity & metabolism 21 (11) (2019)
Yehuda Handelsman, Chantal Mathieu, Stephano Del Prato, Eva Johnsson, Raisa Kurlyandskaya, Nayyar Iqbal, Ricardo Garcia-Sanchez, Julio Rosenstock
Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes. Diabetes, obesity & metabolism 21 (4) (2019)
Lawrence Blonde, Julio Rosenstock, Stephano Del Prato, Robert R Henry, Naim Shehadeh, Juan Pablo Frias, Elisabeth Niemoeller, Elisabeth Souhami, Chen Ji, Vanita R Aroda
Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial. Diabetes care 42 (11) (2019)
David R Matthews, Päivi M Paldánius, Michael Stumvoll, Jackie Han, Giovanni Bader, YannTong Chiang, Pieter Proot, Stephano Del Prato
A pre-specified statistical analysis plan for the VERIFY study: Vildagliptin efficacy in combination with metformin for early treatment of T2DM. Diabetes, obesity & metabolism 21 (10) (2019)
Paola Fioretto, Stephano Del Prato, John B Buse, Ronald Goldenberg, Francesco Giorgino, Daniel Reyner, Anna Maria Langkilde, C David Sjöström, Peter Sartipy, null null
Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study. Diabetes, obesity & metabolism 20 (11) (2018)
Chantal Mathieu, Stephano Del Prato, Fady T Botros, Vivian T Thieu, Imre Pavo, Nan Jia, Axel Haupt, Chrisanthi A Karanikas, Luis-Emilio Garcia-Perez
Effect of once weekly dulaglutide by baseline beta-cell function in people with type 2 diabetes in the AWARD programme. Diabetes, obesity & metabolism 20 (8) (2018)
Stephano Del Prato, Julio Rosenstock, Ricardo Garcia-Sanchez, Nayyar Iqbal, Lars Hansen, Eva Johnsson, Hungta Chen, Chantal Mathieu
Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post-hoc analysis of concomitant add-on versus sequential add-on to metformin and of triple versus dual therapy with metformin. Diabetes, obesity & metabolism 20 (6) (2018)
Kausik K Ray, Lawrence Alan Leiter, Dirk Müller-Wieland, Bertrand Cariou, Helen M Colhoun, Robert R Henry, Francisco J Tinahones, Maja Bujas-Bobanovic, Catherine Domenger, Alexia Letierce, Rita Samuel, Stephano Del Prato
Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial. Diabetes, obesity & metabolism 20 (6) (2018)
Gian Poalo Fadini, Anna Solini, Maria Laura Manca, Giuseppe Penno, Adriano Gatti, Roberto Anichini, Stephano Del Prato, Angelo Avogaro, null null
Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study. Diabetes, obesity & metabolism 21 (2) (2018)
Stephano Del Prato, Robert J Chilton
Practical strategies for improving outcomes in T2DM: The potential role of pioglitazone and DPP4 inhibitors. Diabetes, obesity & metabolism 20 (4) (2017)
Lawrence Alan Leiter, Bertrand Cariou, Dirk Müller-Wieland, Helen M Colhoun, Stephano Del Prato, Francisco J Tinahones, Kausik K Ray, Maja Bujas-Bobanovic, Catherine Domenger, Jonas Mandel, Rita Samuel, Robert R Henry
Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial. Diabetes, obesity & metabolism 19 (12) (2017)

Stephano Del Prato.css-eqlu8i{font-size:small;padding-left:4px;} (Stefano Del Prato)

Publication Activity (10 Years)

Top Topics

Top Venues

Stephano Del Prato (Stefano Del Prato)